SEARCH RESULTS

29 RESULTS

Lon S. Schneider on Biogen/Eisai Halt Phase 3 Aducanumab Trials

COMMENT The outcomes of the aducanumab and crenezumab Phase 3 trials are disappointing but are as expected. Neither of the antibodies showed clinical efficacy evidence in their earlier phase trials. The previous, and regularly repeated, claims of efficacy from ...

Current Filters

  • TYPE: Comment x
  • Commentator: Schneider, Lon S x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE